Lexapro (Escitalopram) Dosing, Administration, and Safety
For adult major depressive disorder, start Lexapro at 10 mg once daily, which is both the recommended and often sufficient dose; increase to a maximum of 20 mg daily only after at least 1 week if clinically indicated, though 10 mg demonstrates equivalent efficacy in most patients. 1
Dosing by Indication
Major Depressive Disorder (MDD)
Adults:
- Starting dose: 10 mg once daily
- Recommended dose: 10 mg once daily (often sufficient)
- Maximum dose: 20 mg once daily
- Titration interval: Wait at least 1 week before increasing 1
The FDA label explicitly notes that while both 10 mg and 20 mg demonstrated effectiveness, trials failed to show greater benefit of 20 mg over 10 mg 1. Research supports this, showing 10 mg is optimal for moderate depression, while 20 mg may be needed only for severe depression 2.
Adolescents (12+ years):
- Starting dose: 10 mg once daily
- Maximum dose: 20 mg once daily
- Titration interval: Wait at least 3 weeks before increasing 1
Generalized Anxiety Disorder (GAD)
Adults:
- Starting dose: 10 mg once daily
- Maximum dose: 20 mg once daily
- Titration interval: Wait at least 1 week 1
Pediatric patients (7+ years):
- Starting dose: 10 mg once daily
- Maximum dose: 20 mg once daily
- Titration interval: Wait at least 2 weeks 1
Administration Instructions
- Timing: Once daily, morning or evening (patient preference)
- Food: With or without food 1
- Consistency: Same time each day improves adherence
Special Populations
Elderly patients: Maximum recommended dose is 10 mg once daily 1, 3. Escitalopram is among the preferred SSRIs for older adults due to favorable tolerability 3.
Hepatic impairment: Maximum recommended dose is 10 mg once daily 1
Renal impairment:
- Mild to moderate: No adjustment needed
- Severe (CrCl <20 mL/min): Dosing not established 1
Critical Safety Considerations
Black Box Warning
Increased suicidal thoughts and behaviors in pediatric and young adult patients. Monitor closely, especially during initial months and after dose changes 1. Not approved for children under 7 years 1.
Monitoring Requirements
Initial monitoring (Weeks 1-2): Contact patient within 1-2 weeks of starting treatment to assess response, adherence, and adverse effects 4. This can be done via telephone or in-person 5.
Ongoing monitoring: Assess therapeutic response and adverse effects regularly. If no adequate response within 6-8 weeks, modify treatment 4.
Contraindications
- MAOIs: Allow 14 days between discontinuing MAOI and starting escitalopram, and vice versa 1
- Linezolid or IV methylene blue: Do not initiate escitalopram in patients receiving these agents 1
- Pimozide: Contraindicated due to QT prolongation risk 1
- Known hypersensitivity to escitalopram or citalopram 1
Major Warnings
Serotonin Syndrome: Risk increases with concomitant serotonergic agents (other SSRIs, SNRIs, triptans, tramadol, St. John's wort, tryptophan). Symptoms include mental status changes, neuromuscular hyperactivity (tremors, clonus, hyperreflexia), and autonomic instability (hypertension, tachycardia, diaphoresis). Can progress to fever, seizures, and death within 24-48 hours 6, 1. Discontinue all serotonergic agents immediately if suspected.
QT Prolongation: Escitalopram can prolong QT interval, though the effect is modest (mean difference 1.3-1.7 ms at therapeutic doses) 3, 7. Avoid in patients with congenital long QT syndrome. Use caution with other QT-prolonging drugs 6.
Bleeding Risk: SSRIs increase bleeding risk, particularly with concurrent NSAIDs, aspirin, antiplatelet agents, or anticoagulants 6, 3. Consider gastroprotection in high-risk patients.
Hyponatremia: Can occur, especially in elderly patients (0.5-12% incidence), typically within first month 3. Monitor sodium levels if symptoms develop (confusion, weakness, unsteadiness).
Activation of Mania/Hypomania: Screen for personal or family history of bipolar disorder before initiating 1. Manic switching can occur in a dose-dependent manner, particularly at 20 mg 8. If mania emerges, discontinue escitalopram.
Common Adverse Effects
Most frequent (≥5% and twice placebo): insomnia, ejaculation disorder, nausea, increased sweating, fatigue, somnolence, decreased libido, anorgasmia 1. Sexual dysfunction occurs in approximately 40% of patients 3.
Drug Interactions
Lower interaction potential: Escitalopram has minimal effects on CYP450 enzymes compared to other SSRIs, resulting in fewer drug-drug interactions 6. However, still avoid combining with:
- Other serotonergic agents
- Drugs prolonging QT interval
- Drugs affecting hemostasis (increases bleeding risk)
Discontinuation
Never stop abruptly. Discontinuation syndrome can occur, characterized by dizziness, fatigue, headaches, nausea, insomnia, paresthesias, anxiety, and irritability 6, 5.
Taper gradually: Reduce dose slowly over time rather than abrupt cessation. If intolerable symptoms emerge during taper, resume previous dose and decrease more gradually 1.
Treatment Duration
First episode MDD: Continue for 4-9 months after satisfactory response 4
Recurrent depression (≥2 episodes): Longer duration beneficial, potentially indefinite 4
Response Assessment
Adequate trial: 6-8 weeks at therapeutic dose before declaring treatment failure 4. However, some improvement should be evident by 2-4 weeks 2.
If inadequate response at 10 mg: Consider increasing to 20 mg, though evidence for additional benefit is limited 1. Alternative strategies include switching to another antidepressant or augmentation 9.
Clinical Pearls
- Starting at higher doses increases risk of self-harm/suicide 5
- Dose escalation above 20 mg (off-label, up to 30-50 mg) has been studied in treatment-resistant cases with some benefit, but tolerability declines above 40 mg 10, 11
- Pregnancy: SSRIs carry risks of persistent pulmonary hypertension of newborn and neonatal adaptation syndrome, but untreated depression also poses risks 3
- Breastfeeding: Escitalopram transfers to breast milk; sertraline and paroxetine preferred if breastfeeding 3